- Quibim is a healthtech company using artificial intelligence to turn medical imaging data into actionable insights for clinicians and researchers.
- Its technology supports earlier disease detection, more accurate diagnoses and personalised treatment decisions across areas such as oncology, neurology and immunology.
- The company’s AI-powered tools are already used across 230+ healthcare and research sites globally and integrate seamlessly into existing clinical workflows.
Website: https://quibim.ai/
Tell Us About Quibim
Quibim is a medical imaging AI company focused on unlocking the full potential of imaging data to improve patient outcomes. Founded with the ambition of turning imaging into a catalyst for precision medicine, the company develops advanced algorithms that convert MRI, CT and PET scans into quantitative insights, enabling clinicians to make faster, more informed decisions.
Its products are designed to fit directly into existing healthcare workflows, allowing hospitals and clinicians to adopt the technology without changing how they work. These tools support the detection and monitoring of diseases such as cancer and neurodegenerative conditions, while also helping pharmaceutical companies run more efficient clinical trials.
Today, Quibim operates globally with offices across Europe and the US, and its technology is already being deployed in real clinical environments, supporting doctors and researchers with more data-driven and consistent insights.
Want to be featured as TechRound’s Startup of the Week? Find out more about this weekly feature, and how to get involved, here.
What Makes Quibim Unique?
Quibim stands out for its focus on transforming standard medical images into measurable, predictive biomarkers that can be applied across both clinical care and drug development.
Unlike many AI solutions that sit alongside existing workflows, Quibim’s tools are designed to integrate directly into hospital systems, enabling adoption at scale without disruption.
The company also operates at the intersection of healthcare and life sciences, supporting not only clinicians but also pharmaceutical companies by improving patient stratification and clinical trial outcomes through imaging-driven insights.
Is There A Market For Quibim?
Yes, and it is growing rapidly. Healthcare systems globally are under increasing pressure from rising imaging volumes, workforce shortages and the need for earlier, more accurate diagnoses.
At the same time, pharmaceutical companies are investing heavily in tools that can improve the efficiency and success rates of clinical trials. Quibim’s technology addresses both challenges by enabling more precise analysis of imaging data and better patient selection.
The company’s presence across more than 230 sites worldwide, alongside partnerships with healthcare providers and life sciences organisations, further demonstrates strong demand for its solutions.
Where Can We Find Quibim?
Quibim operates internationally, with offices in the United States, the United Kingdom and across Spain.
Its technology is used by hospitals, research centres and pharmaceutical companies worldwide. More information can be found on its website: AI for Medical Imaging – Radiomics & Biomarkers – Quibim.
